Now that the holiday season, with all its decadent meals, is over, I wanted to share an update on the diet I mentioned in a column last September. At the time, I was still in the elimination phase of a FODMAP diet (which stands for fermentable oligosaccharides, disaccharides,…
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
Researchers and clinicians are gathering in San Diego and online for the 11th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, a three-day meeting focused on multiple sclerosis (MS) research and care. ACTRIMS 2026, being held Feb. 5-7 at the Marriott Marquis San Diego…
A new study suggests that how certain immune cells respond to Mavenclad (cladribine) may help explain why the treatment works well for some people with multiple sclerosis (MS), but less so for others. The researchers found that regulatory T-cells, or Tregs — immune cells…
Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada living with active secondary progressive multiple sclerosis (SPMS). Teva Canada will take over the promotion, distribution, and commercialization of the oral MS therapy in Canada. The companies say…
Get regular updates to your inbox.
